A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers

Inclusion Criteria

• •Each subject must be willing and able to provide written informed consent for the study
• •Healthy volunteer subjects of both genders, aged 18-64 years old, and any race/ethnicity
• •Subjects with normal blood pressure (between ranges of 120-140/60-80 mmHg) at screening and baseline
• •Subjects with a body mass index (BMI) 18-30 kg/m2
• •Men or woman of childbearing potential using adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly, or surgically sterile) during screening, while receiving the investigational drug, and for 60 days after stopping the investigational drug
• •Female subjects of childbearing potential must have a negative urine pregnancy test at screening
• •Subjects with physiological examination and laboratory values within normal limits (CBC/differential, blood chemistry, iron, Total Iron Binding Capacity (TIBC), urinalysis, ECG and vital signs)
• •Subjects with the ability to comprehend and complete the telephone visits, screening, and site visits
• •Subjects must be able to adhere to dose and visit schedules
• •Subjects who agree to abstain from taking unauthorized medications or supplements or participating in any other clinical trial or experimental treatment during this trial.